View, browse and sort the list of CPhI North America Conference sessions and show floor programming by pass type, track, and format. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

Peter P. Stein, M.D.Deputy Director, Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER)Food and Drug Administration (FDA)

Peter earned his medical degree from University of Pennsylvania and trained at Yale-New Haven Hospital in internal medicine, and in endocrinology and metabolism.  He was on faculty at Yale in the Section of Endocrinology and served as the associate program director for the Primary Care Residency Program.  Subsequently, Peter was the section chief for endocrinology and the program director for internal medicine residency program at the Medical College of Georgia.  Peter joined Bristol-Myers Squibb in 1999, subsequently working at Merck, Janssen, and finishing his career in industry at Merck as Vice-president for late-stage development in Diabetes and Endocrinology.  During his industry career, Peter led development programs for several currently approved diabetes medications, and has worked on a wide range of programs from discovery through early and late clinical development.  He is a clinical associate professor at the Robert Wood Johnson Medical School, where he maintained a practice in endocrinology for many years.  Peter joined FDA in late 2016 as the Deputy Director, Office of New Drugs, CDER.